DOCSLIB.ORG

Innual /Wel 50 Year90f the Wellcome Trust

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Innual /Wel 50 Year90f the Wellcome Trust INNUAL /WEL 50 YEAR90F THE WELLCOME TRUST 1936 -1986 t;~~~~:··':.:_J~'·:~~:_':"'~ ._-, --- -, .-.l ~ \ Sixteenth Report ••• 1984 - 1986 1 Park Square West, London NWI 4LJ First published 1987 © The Trustees of The Wellcome Trust 1987 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any or by any means electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the Wellcome Trust. Cover designed by Valin Pollen Ltd., London. Printed by Cranford Press Limited, Croydon, Surrey ISBN 1-869835--D1-8 Sir Ilcnry Solomon Wcllcomc (I SS3·I '}J(,) Oil p aintin ~ by Sir Hugh Goldwi n Riviere. 19(1(, (We llcornc Institute Library. Lond on) On Wedn esday, ISth February 19i1 7, a serv ice was held in the Crypt of St. Paul's Cathedral to honour the memor y of Sir Henry Wcllcorne ( lil53-1936), patron of medical research and history and fou nder of the Wcll corne Tr ust. A memo rial tablet was un ve iled by Sir David Steel. C hai rma n o f th e Wc llcum c Trustees, FOREWORD In this memorable Jubilee Year, I feel justified in adding, for the first time, a short foreword to this special Sixteenth Biennial Report. It not only covers the work of the Trust during the past two years 1984-1986, but also reports on some of the Fiftieth Anniversary celebrations, of which the highlight was the visit by Her Majesty The Queen and His Royal Highness The Duke of Edinburgh. An excellent history of the Trust has also been written jointly by Professor A.R. Hall and Dr. B.A. Bembridge to mark the Jubilee. It is entitled Physic and Philanthropy and describes the Trust's activities since its inception in 1936. The last two years have been exciting ones for us. Not only has the Trust attained its fiftieth year, but the Trustees have put on the open market twenty-one per cent of their shareholding in Wellcome pic. I would like to express my own personal tribute to the work done by the Director, his staff and everyone associated with the Trust in achieving these important milestones. Chairman Sir David Steel BOARD OF TRUSTEES Chairman: Sir David Steel, DSO, MC, TO Deputy Chairman: C.E. Gordon Smith, CB, MD, FRCP, FRCPath Trustees: The Rt. Hon. the Lord Swann, FRS Professor Sir Stanley Peart, MD, FRCP, FRS Professor Sir William Paton, CBE, OM, FRCP, FRS I. Helen Muir, CBE, MA, DPhil, DSc, FRS Roger G. Gibbs Secretary to the Trustees: P.O. Williams, MA, MB, FRCP CONTENTS I INTRODUCTION AND POLICY 1 II THE TRUSTEES AND THEIR STAFF 11 III DIVERSIFICATION AND THE FLOTATION 19 IV 50 YEARS OF THE WELLCOME TRUST 25 A. Physic and Philanthropy 27 B. Thoughts on the Wellcome Trust 1963 - 1982 by Lord Franks 35 C. Fifty Years of the Administration of the Trust 41 D. 50th Anniversary Celebrations 49 V SUPPORT OF MEDICAL RESEARCH, SPECIAL FELLOWSHIPS AND SENIOR LECTURESHIPS IN THE U.K. 59 A. Senior Research Fellowships in Clinical Science 63 B. Senior Basic Biomedical Fellowships 71 C. Wellcome Senior Lectureships 75 D. Wellcome Lectureships 89 E. Research Training Fellowships in Clinical Epidemiology 97 F. Research Training Fellowships for Medical and Dental Graduates 101 VI SUPPORT FOR SELECTED SUBJECT AREAS 107 A. Mental Health and Neurosciences 109 B. Tropical Medicine and Infectious Diseases 121 C. Veterinary Medicine 145 D. Vision Research 157 E. Clinical Research 165 F. Biochemistry and Cell Biology 177 G. Physiology and Pharmacology 199 H. Major Equipment 221 VII SUPPORT OF NON· TROPICAL MEDICAL RESEARCH OVERSEAS 227 A. European Programme 229 B. Other Overseas Awards 243 C. Travel Grants 251 VIII HISTORY OF MEDICINE 253 A. Wellcome Institute for the History of Medicine 255 B. Units in the History of Medicine 263 C. Grants for the support of the History of Medicine 269 IX WELLCOME TROPICAL INSTITUTE 277 X MEDALS AND PRIZES 285 XI INDEXES 289 INTRODUCTION AND POLICY INTRODUCTION AND POLICY The central event in the past two years was the flotation of the Wellcome Foundation Ltd., (as Wellcome pIc) as a public company. This development was of such significance to the entirety of Wellcome's creations, that it is described in some detail in a separate section (see pp. 19-23). Here it is sufficient to say that in one jump it will raise the Trust's income from £20 to £35 million and therefore lead to many major changes in the programme, organisation and staff and accommodation requirements of the Trust. In order to make the process of change less sudden, the Trustees anticipated the growth by one year by using a considerable proportion of their reserves in the first year of this biennium. The budget for the two years was in 1984/85 £22.75 million, and in 1985/86 £30.4 million. The total of £53.5 million can be compared with £29.5 million over the previous two years. This scale of activity in Britain, where the Trust allocates most of its income, makes it the largest general medical research charity in Britain and com­ parable in size with the funds available to the Medical Research Council (M.R.C.) for support of research in the universities. While it is difficult to measure the actual contribution of various sections of the community to medical research, the figures from the Association of Medical Research Charities (A.M.R.e.) indicate that the charitable contribution is compa­ rable to that of the M.R.e. overall and about twice as much as the M.R.C. provides for grants to the universities. This is a change in balance which has begun to affect the whole organisation of medical research in Britain. While the government has failed to expand its contribution, the charities have grown and with it their significance. Whereas previously the charities could be classed as alternative sources of funding for university research, now they have become of such significance that some institutions are in the position of receiving the majority of their support from private sources and the balance from the government. Our universities and medical schools can be seen to be gearing themselves to this new situation and hence their attitude to donors has evolved. A report from the Advisory Board of Research Councils (A.B.R.C.) on the private sector funding of scientific research said: "Our conclusion is that there wouldappear to be somegroundfor looking to the majorfoundations for increasedcollaborative funding in the medical field but only in certain circumstances and, overall, to only a limited extent. It is clear above all that the foundations would need reassurance that Government was not looking to them to assume responsibility for meeting basicresearchneedsand wasnot seeking to enticethe foundations 3 into the formal Governmental funding mechanisms for such research. We respect the determination of the foundations to retain their independence, flexibility and diversity." On the other hand, the central role of the National Health Service on the clinical side limits the opportunity for developing academic clinical re­ search. The example of the Senior Registrar quota system in which the Department of Health and Social Security failed to recognise the level of input of the charities to academic medical training, forced the A.M.R.e. to develop into a charitable company in order to safeguard its members' interests which, of course, means the interest of the medical research com­ munity. What is apparent is that the long established system of negotiation between the universities, research councils and government, is now not enough as the government fails to provide the level of support necessary to maintain Britain in the front-line of medical research. This brings one to consider the overall turmoil that has continued to affect the academic medical world in the past few years. In medicine, this has led for example to the amalgamation of medical schools in London, Middlesex and Uni­ versity College, Charing Cross and Westminster, and the exploration of the future of the Clinical Research Centre and the Royal Postgraduate Medical School. The Royal College of Physicians feels the problem of academic medicine to be of such significance that it is preparing a report on the subject. In the report it draws attention to a variety of factors including levels of salary and career prospects. In the veterinary world this has also been a time of scrutiny and intros­ pection. There is a general opinion that farming has become so efficient that the need for more government investment in research is not apparent. As a consequence, there have been enormous cuts in the establishments of the Agriculture and Food Research Council and the veterinary schools are being examined to see how they may be cut down in number or amal­ gamated. Overall, a scene which has not augured well for veterinary re­ search morale and which is possibly reflected in the difficulty in spending the funds allocated to this field by the Trustees. While the flotation of Wellcome pic and the general political scene for academic human and animal medicine has been at the forefront of our minds during the past two years as we have sought to develop new policies for the use of our extra income, not far from the surface was the 50th anniversary of Sir Henry Wellcome's death on July 25th 1936. The cele­ bration of a golden jubilee is, inevitably, a time for reflection· on the 4 achievement of an organisation and so the Trustees were very pleased when Professor A. Rupert Hall, together with Dr.
Load more

Recommended publications
  • BMC Systems Biology Biomed Central
    BMC Systems Biology BioMed Central Commentary Open Access The long journey to a Systems Biology of neuronal function Nicolas Le Novère* Address: EMBL-EBI, Wellcome-Trust Genome Campus, CB10 1SD Hinxton, UK Email: Nicolas Le Novère* - [email protected] * Corresponding author Published: 13 June 2007 Received: 13 April 2007 Accepted: 13 June 2007 BMC Systems Biology 2007, 1:28 doi:10.1186/1752-0509-1-28 This article is available from: http://www.biomedcentral.com/1752-0509/1/28 © 2007 Le Novère; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Computational neurobiology was born over half a century ago, and has since been consistently at the forefront of modelling in biology. The recent progress of computing power and distributed computing allows the building of models spanning several scales, from the synapse to the brain. Initially focused on electrical processes, the simulation of neuronal function now encompasses signalling pathways and ion diffusion. The flow of quantitative data generated by the "omics" approaches, alongside the progress of live imaging, allows the development of models that will also include gene regulatory networks, protein movements and cellular remodelling. A systems biology of brain functions and disorders can now be envisioned. As it did for the last half century, neuroscience can drive forward the field of systems biology. 1 Modelling nervous function, an ancient quest To accurately model neuronal function presents many Neurosciences have a long and successful tradition of challenges, and stretches the techniques and resources of quantitative modelling, where theory and experiment computational biology to their limits.
    [Show full text]
  • EMJ-5.2-2020-4.Pdf
    Contents + EDITORIAL BOARD 4 + CONGRESS REVIEW Review of the European Conference on Rare Diseases, 10 15th – 16th May 2020 + FEATURE The COVID-19 Conundrum and Cancer – Making Perfect Sense of 19 Imperfect Data Utkarsh Acharya + SYMPOSIUM REVIEW Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative 22 Colitis: The Missing Piece of The Puzzle? + POSTER REVIEWS Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction 29 of Atherosclerotic Cardiovascular Disease Events Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent 37 Real-World Data + INTERVIEWS Data from the AUGUSTUS Trial Adds an Important Piece to the 42 Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Renato D. Lopes and Amit N. Vora Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: 47 An Expert Clinical Consensus Vallerie McLaughlin and Sean Gaine 2 EMJ • June 2020 • Cover Image © Anna Grigorjeva / 123rf.com EMJ “It is more important than ever that information is disseminated rapidly and responsibly in the face of such global threats” Spencer Gore, CEO + ARTICLES Editor's Pick: Bone-Related Markers of Cardiovascular Disease 54 Ernesto Maddaloni et al. National Institute for Health and Care Excellence (NICE) Guidelines on 63 Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management Rhys H. Thomas and Jacob Brolly The Role of Next-Generation Sequencing and Reduced Time to 76 Diagnosis In Haematological Diseases: Status Quo and Prospective Overview of Promising Molecular Testing Approaches Christina Ranft Bernasconi et al. Sebaceous Carcinoma: A Rare Extraocular Presentation of the Cheek 85 Ritu Swali et al.
    [Show full text]
  • Haemophilia: Recent History of Clinical Management
    HAEMOPHILIA: RECENT HISTORY OF CLINICAL MANAGEMENT The transcript of a Witness Seminar held at the Wellcome Institute for the History of Medicine, London, on 10 February 1998 Edited by D A Christie and E M Tansey HAEMOPHILIA: RECENT HISTORY OF CLINICAL MANAGEMENT Participants Dr Derek Bangham Professor Ilsley Ingram Dr Ethel Bidwell Dr Peter Jones Sir Christopher Booth Professor Christine Lee (Chair) Dr Brian Colvin Dr James Matthews Dr Angela Dike Mrs Riva Miller Mr Ross Dike Dr Charles Rizza Dr Helen Dodsworth Rev Alan Tanner Professor Stuart Douglas* Dr Tilli Tansey Professor Robert Duthie Professor Edward Tuddenham Dr David Evans Dr David Tyrrell Dr Sheila Howarth Mr Clifford Welch Others present at the meeting: Dr Trevor Barrowcliffe, Ms Jacqui Marr, Dr J K Smith, Miss Rosemary Spooner Apologies: Professor Jean-Pierre Allain, Dr Donald Bateman, Dr Rosemary Biggs, Mrs Peggy Britten,** Professor Judith Chessells, Dr Audrey Dawson, Mr Ron Hutton, Professor Ralph Kekwick, Professor Sir David Weatherall *Deceased 15 November 1998 **Deceased 1 March 1999 2 Haemophilia: Recent history Professor Christine Lee:1 I think haemophilia is one of the best areas of clinical medicine where we have seen a very rapid introduction of scientific discovery into clinical practice. All of us who work on haemophilia realize that this has gone on very much with cooperation between the patients and the scientists and the doctors. I first saw haemophilia in 1967 when I was a medical student in Oxford and we were doing our orthopaedics at the Nuffield Orthopaedic Hospital. I have a very clear memory of a ward of little boys with their legs strung up, their arms strung up, and I think there was a schoolroom nearby.
    [Show full text]
  • Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation
    CLINICAL PHARMACOLOGY IN THE UK, c. 1950–2000: INDUSTRY AND REGULATION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 25 September 2007 Edited by L A Reynolds and E M Tansey Volume 34 2008 ©The Trustee of the Wellcome Trust, London, 2008 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2008 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 118 9 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and L A Reynolds ix Introduction Professor Parveen Kumar xxiii Transcript Edited by L A Reynolds and E M Tansey 1 References 73 Biographical notes 89 Glossary 103 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. Reproduced by permission of AstraZeneca. 6 Figure 2 A summary of the organization of clinical trials. Adapted from www.clinicaltrials.gov/ct2/info/glossary (visited 1 May 2008). 10 Figure 3 Clinical trial certificates (CTC) and clinical trial exemption (CTX), 1972–1985. Adapted from Speirs (1983) and Speirs (1984).
    [Show full text]
  • Cambridge's 92 Nobel Prize Winners Part 2 - 1951 to 1974: from Crick and Watson to Dorothy Hodgkin
    Cambridge's 92 Nobel Prize winners part 2 - 1951 to 1974: from Crick and Watson to Dorothy Hodgkin By Cambridge News | Posted: January 18, 2016 By Adam Care The News has been rounding up all of Cambridge's 92 Nobel Laureates, celebrating over 100 years of scientific and social innovation. ADVERTISING In this installment we move from 1951 to 1974, a period which saw a host of dramatic breakthroughs, in biology, atomic science, the discovery of pulsars and theories of global trade. It's also a period which saw The Eagle pub come to national prominence and the appearance of the first female name in Cambridge University's long Nobel history. The Gender Pay Gap Sale! Shop Online to get 13.9% off From 8 - 11 March, get 13.9% off 1,000s of items, it highlights the pay gap between men & women in the UK. Shop the Gender Pay Gap Sale – now. Promoted by Oxfam 1. 1951 Ernest Walton, Trinity College: Nobel Prize in Physics, for using accelerated particles to study atomic nuclei 2. 1951 John Cockcroft, St John's / Churchill Colleges: Nobel Prize in Physics, for using accelerated particles to study atomic nuclei Walton and Cockcroft shared the 1951 physics prize after they famously 'split the atom' in Cambridge 1932, ushering in the nuclear age with their particle accelerator, the Cockcroft-Walton generator. In later years Walton returned to his native Ireland, as a fellow of Trinity College Dublin, while in 1951 Cockcroft became the first master of Churchill College, where he died 16 years later. 3. 1952 Archer Martin, Peterhouse: Nobel Prize in Chemistry, for developing partition chromatography 4.
    [Show full text]
  • Wellcome Four Year Phd Programme in Integrative Cell Mechanisms
    2021 Wellcome Four Year PhD Programme in Integrative Cell Mechanisms Training the next generation of Molecular Cell Biologists Background and Aims of Programme The Wellcome Four Year PhD Programme in Integrative Cell Mechanisms (iCM) is closely associated with the Wellcome Centre for Cell Biology and trains the next generation of cell and molecular biologists in the application of quantitative methods to understand the inner workings of distinct cell types in different settings. A detailed understanding of normal cellular function is required to investigate the molecular cause of disease and design future treatments. However, data generated by biological research requires increasingly complex analysis with technological advances in sequencing, mass spectrometry/proteomics, super-resolution microscopy, Wellcome Centre for Cell Biology 2021 synthetic and structural biology generating increasingly large, complex datasets. In addition, innovations in computer sciences and informatics are transforming data acquisition and analysis and breakthroughs in physics, chemistry and engineering allow the development of devices, molecules and instruments that drive the biological data revolution. Exploiting technological advances to transform our understanding of cellular mechanisms will require scientists who have been trained across the distinct disciplines of natural sciences, engineering, informatics and mathematics. To address this training need, iCM PhD projects are cross-disciplinary involving two primary supervisors with complementary expertise. Supervisor partnerships pair quantitative scientists with cell biologists ensuring that students develop pioneering cross-disciplinary collaborative projects to uncover cellular mechanisms relevant to health and disease. We aim to recruit students with a variety of backgrounds across the biological and physical sciences, including Biochemistry, Biomedical Science, Cell Biology, Chemistry, Computational Data Sciences, Engineering, Genetics, Mathematics, Molecular Biology and Physics.
    [Show full text]
  • Female Fellows of the Royal Society
    Female Fellows of the Royal Society Professor Jan Anderson FRS [1996] Professor Ruth Lynden-Bell FRS [2006] Professor Judith Armitage FRS [2013] Dr Mary Lyon FRS [1973] Professor Frances Ashcroft FMedSci FRS [1999] Professor Georgina Mace CBE FRS [2002] Professor Gillian Bates FMedSci FRS [2007] Professor Trudy Mackay FRS [2006] Professor Jean Beggs CBE FRS [1998] Professor Enid MacRobbie FRS [1991] Dame Jocelyn Bell Burnell DBE FRS [2003] Dr Philippa Marrack FMedSci FRS [1997] Dame Valerie Beral DBE FMedSci FRS [2006] Professor Dusa McDuff FRS [1994] Dr Mariann Bienz FMedSci FRS [2003] Professor Angela McLean FRS [2009] Professor Elizabeth Blackburn AC FRS [1992] Professor Anne Mills FMedSci FRS [2013] Professor Andrea Brand FMedSci FRS [2010] Professor Brenda Milner CC FRS [1979] Professor Eleanor Burbidge FRS [1964] Dr Anne O'Garra FMedSci FRS [2008] Professor Eleanor Campbell FRS [2010] Dame Bridget Ogilvie AC DBE FMedSci FRS [2003] Professor Doreen Cantrell FMedSci FRS [2011] Baroness Onora O'Neill * CBE FBA FMedSci FRS [2007] Professor Lorna Casselton CBE FRS [1999] Dame Linda Partridge DBE FMedSci FRS [1996] Professor Deborah Charlesworth FRS [2005] Dr Barbara Pearse FRS [1988] Professor Jennifer Clack FRS [2009] Professor Fiona Powrie FRS [2011] Professor Nicola Clayton FRS [2010] Professor Susan Rees FRS [2002] Professor Suzanne Cory AC FRS [1992] Professor Daniela Rhodes FRS [2007] Dame Kay Davies DBE FMedSci FRS [2003] Professor Elizabeth Robertson FRS [2003] Professor Caroline Dean OBE FRS [2004] Dame Carol Robinson DBE FMedSci
    [Show full text]
  • Calling Time the Nation’S Drinking As a Major Health Issue
    Calling Time The Nation’s drinking as a major health issue 12 250 10 200 8 150 6 100 4 50 to income Price relative 2 Litres of alcohol per person aged 15+Litres 0 0 1960 1964 1968 1970 1976 1980 1984 1988 1992 1996 2000 A report from the Academy of Medical Sciences With support from March 2004 The independent Academy of Medical Sciences promotes advances in medical science and public health and campaigns to ensure these are translated as quickly as possible into benefits for society. The Academy’s 750 Fellows are the United Kingdom’s leading medical scientists from hospitals, academia, industry and the public service. The aims of the Academy are to: • give national and international leadership in the medical sciences; • promote the application of research to the practice of medicine and to the advancement of human health and welfare; • promote the aims and ethos of medical sciences with particular emphasis on excellence in research and training; • enhance public understanding of the medical sciences and their impact on society; • assess and advise on issues of medical science of public concern. The Academy of Medical Sciences was established in 1998 following the recommendations of a working group chaired by Sir Michael Atiyah, Past President of the Royal Society. There is an elected Council of 22 Fellows that includes the five Officers of the Academy: President Sir Keith Peters, FRS, PMedSci Vice-President (Clinical) Lord Turnberg, FMedSci Vice-President (Non-clinical) Sir John Skehel, FRS, FMedSci Treasurer Sir Colin Dollery, FMedSci Registrar Professor Patrick Vallance, FMedSci The Academy is a registered charity and a company limited by guarantee.
    [Show full text]
  • A Case Study of Glaxosmithkline Plc )
    )l GROWTH THROUGH MERGER: A CASE STUDY OF GLAXOSMITHKLINE PLC ) / BY JUNE WANGARI UNIVERSITY OF NAIR03J LOWER KABETE LIBRARY A MANAGEMENT RESEARCH PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF MASTER OF BUSINESS ADMINISTRATION (MBA), SCHOOL OF BUSINESS, UNIVERSITY OF NAIROBI JULY, 2008 DECLARATION I declare that this project is my original work and has never been presented for academic purposes in any other University. CANDIDATE: JUNE WANGARI DATE .(.91. This research project has been submitted for examination with my approval as the University Supervisor SIGNED. DATE. Prof. Evans Aosa Department Of Business Administration, School Of Business, University Of Nairobi 11 DEDICATION I dedicate this project to my daughter Jemima, who was born within the first year of my post graduate studies. And now that she is in kindergarten, I see that I have instilled in her the love for reading and learning and I trust that she will go very far. iii ACKNOWLEDGEMENT I thank God for seeing me through my studies as I tried to balance between my family, my work and my studies. I wish to acknowledge the contributions that were made in the course of this project by several individuals and organizations. I wish to acknowledge gratefully the following people, whose effort influenced the content and direction of this project. My first thanks go to my Supervisor Prof. Evans Aosa for his constant analytical criticism and encouragement. Thanks a lot. I wish to thank my friends for a lot of support and encouragement to me in pursuit of this goal.
    [Show full text]
  • Harper, Peter: Transcript of a Video Interview (06-Jun-2015)
    History of Modern Biomedicine Research Group School of History, Queen Mary University of London Mile End Road, London E1 4NS website: www.histmodbiomed.org VIDEO INTERVIEW TRANSCRIPT Harper, Peter: transcript of a video interview (06-Jun-2015) Interviewer: Tilli Tansey Transcriber: Debra Gee Editors: Tilli Tansey, Alan Yabsley Date of publication: 20-Mar-2017 Date and place of interview: 06-Jun-2015; Glasgow Publisher: Queen Mary University of London Collection: History of Modern Biomedicine Interviews (Digital Collection) Reference: e2017093 Number of pages: 4 DOI: 10.17636/01021439 Acknowledgments: The project management of Mr Adam Wilkinson is gratefully acknowledged. The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity (no. 210183). The current interview has been funded by the Wellcome Trust Strategic Award entitled “Makers of modern biomedicine: testimonies and legacy” (2012-2017; awarded to Professor Tilli Tansey). Citation: Tansey E M (intvr); Tansey E M, Yabsley A (eds) (2017) Harper, Peter: transcript of a video interview (06-Jun- 2015). History of Modern Biomedicine Interviews (Digital Collection), item e2017093. London: Queen Mary University of London. Related resources: items 2017094 - 2017099, History of Modern Biomedicine Interviews (Digital Collection) Note: Video interviews are conducted following standard oral history methodology, and have received ethical approval (reference QMREC 0642). Video interview transcripts are edited only for clarity and factual accuracy. Related material has been deposited in the Wellcome Library. © The Trustee of the Wellcome Trust, London, 2017 History of Modern Biomedicine Interviews (Digital Collection) - Harper, P e2017093 | 2 Harper, Peter: transcript of a video interview (06-Jun-2015)* Biography: Professor Peter Harper (b.
    [Show full text]
  • Science & Policy Meeting Jennifer Lippincott-Schwartz Science in The
    SUMMER 2014 ISSUE 27 encounters page 9 Science in the desert EMBO | EMBL Anniversary Science & Policy Meeting pageS 2 – 3 ANNIVERSARY TH page 8 Interview Jennifer E M B O 50 Lippincott-Schwartz H ©NI Membership expansion EMBO News New funding for senior postdoctoral In perspective Georgina Ferry’s enlarges its membership into evolution, researchers. EMBO Advanced Fellowships book tells the story of the growth and ecology and neurosciences on the offer an additional two years of financial expansion of EMBO since 1964. occasion of its 50th anniversary. support to former and current EMBO Fellows. PAGES 4 – 6 PAGE 11 PAGES 16 www.embo.org HIGHLIGHTS FROM THE EMBO|EMBL ANNIVERSARY SCIENCE AND POLICY MEETING transmissible cancer: the Tasmanian devil facial Science meets policy and politics tumour disease and the canine transmissible venereal tumour. After a ceremony to unveil the 2014 marks the 50th anniversary of EMBO, the 45th anniversary of the ScienceTree (see box), an oak tree planted in soil European Molecular Biology Conference (EMBC), the organization of obtained from countries throughout the European member states who fund EMBO, and the 40th anniversary of the European Union to symbolize the importance of European integration, representatives from the govern- Molecular Biology Laboratory (EMBL). EMBO, EMBC, and EMBL recently ments of France, Luxembourg, Malta, Spain combined their efforts to put together a joint event at the EMBL Advanced and Switzerland took part in a panel discussion Training Centre in Heidelberg, Germany, on 2 and 3 July 2014. The moderated by Marja Makarow, Vice President for Research of the Academy of Finland.
    [Show full text]
  • Bulletin of Tibetology
    Bulletin of Tibetology NEW SERIES 1990 No. 1-3 9 November 1990 SIKKIM RESEARCH INSTITUTE OF TIBETOLOOY GANGTOK, INDIA - The Bulletin ofTibetology seeks to serve the specialist as well as the general reader with an interest in this field of study. The motif portraying the Stupa on the mountains suggests the dimensions of the field - EDnORS JAMPAL K. RECHUNG KUNGA YONTEN HOCHaISANG BHAJAGOVINDA GHOSH Bulletin of Tibetology NEW SERIES 1990 No. 1-3 9 November 1990 SIKKIM RESEARCH INSTITUTE OF TIBETOLOGY GANGTOK, INDIA LCHAGS-RTA : LHABAB DUECHBN 9 November 1990 Price per copy Rs. 25 1- 7/91 PUBLISHED BY TIlE DIRECTOR SIKKIM RESEARCH INSTITUTE OF TIBETOLOOY GANGTOK - 737 101. SIKKIM PRINTED AT HIMALINDIA PHOTO OFFSET NAM NAM ROAD,GANGTOK CONTENTS Page 1 SAKY AMUNI'S FINAL NIRVANA - David L. Snellgrove 5 2 BUDDHARUPA -- OBSERVATION ON THE EVOLUTION OF BUDDHA IMAGE - Ninnal C. Sinha 18 3 HINAY ANA AND MAHAYANA - A BROAD OUTLINE - Anukul Chandra Banerjee 23 4 VAIDURYA - Marianne Winder 27 5 THE CONFLICT BETWEEN THE BUDDlllST AND THE NAlY AYIKA PHILOSOPHERS - A BRIEF SURVEY - Dr. Sanjit Kumar Sadhukhan 39 6 THE BUDDlllST PAINTINGS AND ICONOGRAPHY ACCORDING TO TIBETAN SOURCES - J.K. Rechung 55 7 NOTES & TOPICS - H.R. Bhattacharyya 65 CONTRmUTORS IN THIS ISSUE: DAVID L. SNELLGROVE, Fellow of the British Academy. formerly Professor of Tibetan. the School of Oriental and African Studies. University of London. Had travelled extensively in India and Nepal. made critical studies of the Hevajra-Tantra on the basis of extant Sanskrit mss and Tibetan version. Made Critical study on early Religion of Tibet-Bon.
    [Show full text]